Results from the extensive research conducted on PPARs over the years have elucidated that PPAR expression is altered in lung cancer, especifically PPARγ that has been targeted using varieties of agonists and antagonists in order to treat different lung cancer cell lines in vitro and models in vivo. Here, PPARA is linked to lung carcinoma.